These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20698223)

  • 1. Association between tumor necrosis factor-alpha and Fc-gamma receptor polymorphisms with infliximab in Crohn's disease.
    Tomita K; Chiba T; Sugai T; Habano W
    Hepatogastroenterology; 2010; 57(99-100):535-9. PubMed ID: 20698223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
    Pierik M; Vermeire S; Steen KV; Joossens S; Claessens G; Vlietinck R; Rutgeerts P
    Aliment Pharmacol Ther; 2004 Aug; 20(3):303-10. PubMed ID: 15274667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
    Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study.
    Louis EJ; Watier HE; Schreiber S; Hampe J; Taillard F; Olson A; Thorne N; Zhang H; Colombel JF
    Pharmacogenet Genomics; 2006 Dec; 16(12):911-4. PubMed ID: 17108815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.
    Louis E; Vermeire S; Rutgeerts P; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Malaise M; Belaiche J
    Scand J Gastroenterol; 2002 Jul; 37(7):818-24. PubMed ID: 12190096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of linkage between lymphotoxin alpha haplotype and polymorphisms in 5'-flanking region of tumor necrosis factor alpha gene associated with efficacy of infliximab for Crohn's disease patients.
    Ozeki T; Furuya Y; Nagano C; Matsui C; Takayanagi R; Yokoyama H; Yamada Y
    Mutat Res; 2006 Dec; 602(1-2):170-4. PubMed ID: 17049565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Independent contribution of HLA-DRB1 and TNF alpha promoter polymorphisms to the susceptibility to Crohn's disease.
    Kawasaki A; Tsuchiya N; Hagiwara K; Takazoe M; Tokunaga K
    Genes Immun; 2000 Aug; 1(6):351-7. PubMed ID: 11196680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease.
    Agnholt J; Kaltoft K
    Cytokine; 2001 Aug; 15(4):212-22. PubMed ID: 11563881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of TNF-alpha/LTA polymorphisms with Crohn's disease in Koreans.
    Yang SK; Lee SG; Cho YK; Lim J; Lee I; Song K
    Cytokine; 2006 Jul; 35(1-2):13-20. PubMed ID: 16931032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
    Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P;
    Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms of the TNF gene and the TNF receptor superfamily member 1B gene are associated with susceptibility to ulcerative colitis and Crohn's disease, respectively.
    Sashio H; Tamura K; Ito R; Yamamoto Y; Bamba H; Kosaka T; Fukui S; Sawada K; Fukuda Y; Tamura K; Satomi M; Shimoyama T; Furuyama J
    Immunogenetics; 2002 Mar; 53(12):1020-7. PubMed ID: 11904678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis: polymorphisms in TNF-alpha gene promoter and Crohn's disease.
    Han Z; Li C; Han S; Han Y; Qiu J; Shi Y; Wang J; Sun A; Ding J; Wu K; Fan D
    Aliment Pharmacol Ther; 2010 Jul; 32(2):159-70. PubMed ID: 20456305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab.
    Medrano LM; Taxonera C; Márquez A; Barreiro-de Acosta M; Gómez-García M; González-Artacho C; Pérez-Calle JL; Bermejo F; Lopez-Sanromán A; Martín Arranz MD; Gisbert JP; Mendoza JL; Martín J; Urcelay E; Núñez C
    Hum Immunol; 2014 Jan; 75(1):71-5. PubMed ID: 24121042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease.
    Ainsworth MA; Bendtzen K; Brynskov J
    Am J Gastroenterol; 2008 Apr; 103(4):944-8. PubMed ID: 18028512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: association with clinical phenotypes.
    Waschke KA; Villani AC; Vermeire S; Dufresne L; Chen TC; Bitton A; Cohen A; Thomson AB; Wild GE
    Am J Gastroenterol; 2005 May; 100(5):1126-33. PubMed ID: 15842589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.
    Schnitzler F; Fidder H; Ferrante M; Noman M; Arijs I; Van Assche G; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):492-500. PubMed ID: 18832518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNF-alpha -308A promoter polymorphism is associated with enhanced TNF-alpha production and inflammatory activity in Crohn's patients with fistulizing disease.
    González S; Rodrigo L; Martínez-Borra J; López-Vázquez A; Fuentes D; Niño P; Cadahía V; Saro C; Dieguez MA; López-Larrea C
    Am J Gastroenterol; 2003 May; 98(5):1101-6. PubMed ID: 12809834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.